- Jazz Pharmaceuticals (NASDAQ:JAZZ) priced $850M aggregate principal amount of 3.125% exchangeable senior notes due 2030 in a private offering by its subsidiary Jazz Investments I.
- The issuer also granted the initial purchasers an option to purchase additional $150M notes.
- The sale of the notes is expected to close on September 6, 2024.
- The company also repurchased ~$150M of its ordinary shares from purchasers of the notes in privately negotiated transactions.
